E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

被引：0
|
作者：
Hochster, Howard S.
Catalano, Paul J.
Mitchell, Edith P.
Cohen, Deirdre Jill
O'Dwyer, Peter J.
Benson, Al Bowen
机构：
[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] NYU, Inst Canc, New York, NY USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3665
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Naoki Nagata
    Hiromichi Maeda
    Keiichiro Ishibashi
    Keiji Hirata
    Akitaka Makiyama
    Shigeyoshi Iwamoto
    Hiroyoshi Takemoto
    Mitsunobu Imasato
    Yoichiro Yoshida
    Yoshinori Munemoto
    Chihiro Tanaka
    Yoshitaka Morita
    Yoshihiro Hotta
    Atsushi Toyofuku
    Takeshi Nagasaka
    Satoshi Morita
    Junichi Sakamoto
    Hideyuki Mishima
    Medical Oncology, 2019, 36
  • [42] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)
    Nagata, Naoki
    Maeda, Hiromichi
    Ishibashi, Keiichiro
    Hirata, Keiji
    Makiyama, Akitaka
    Iwamoto, Shigeyoshi
    Takemoto, Hiroyoshi
    Imasato, Mitsunobu
    Yoshida, Yoichiro
    Munemoto, Yoshinori
    Tanaka, Chihiro
    Morita, Yoshitaka
    Hotta, Yoshihiro
    Toyofuku, Atsushi
    Nagasaka, Takeshi
    Morita, Satoshi
    Sakamoto, Junichi
    Mishima, Hideyuki
    MEDICAL ONCOLOGY, 2019, 36 (06)
  • [43] Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy forMetastatic Colorectal Cancer
    Louvet, C.
    Andre, T.
    Gamelin, E.
    Hebbar, M.
    Mabro, M.
    Bennamoun, M.
    Rassam, H.
    de Gramont, A.
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [44] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [45] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [46] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [47] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [48] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [49] Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial
    Passardi, A.
    Scarpi, E.
    Fontana, A.
    Cavanna, L.
    Ruscelli, S.
    Turci, D.
    Lorusso, V.
    Mucciarini, C.
    Tassinari, D.
    Ragazzini, A.
    Valgiusti, M.
    Ulivi, P.
    Frassineti, G. L.
    Amadori, D.
    ANNALS OF ONCOLOGY, 2015, 26
  • [50] Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Sawada, Kentaro
    Nakamura, Michio
    Muto, Osamu
    Sogabe, Susumu
    Shindo, Yoshiaki
    Ishiguro, Atsushi
    Sato, Atsushi
    Tsuji, Yasushi
    Dazai, Masayoshi
    Okuda, Hiroyuki
    Sasaki, Takahide
    Harada, Kazuaki
    Nakano, Shintaro
    Nakatsumi, Hiroshi
    Sekiguchi, Mari
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345